Akeso, Inc. (9926) has entered into an agreement with JumpCan Pharmaceutical Group Co., Ltd. and Jiangsu Jiyuan Pharmaceutical Co., Ltd., both wholly owned subsidiaries of Hubei JumpCan Pharmaceutical Co., Ltd. (600566.SS), granting exclusive commercialization rights within the People’s Republic of China (excluding Hong Kong, Macao, and Taiwan) for the independently developed and approved product 伊喜寧® (ebronucimab injection).

伊喜寧® was approved for market launch in September 2024 for primary hypercholesterolemia and mixed hyperlipidemia, including heterozygous familial hypercholesterolemia and hypercholesterolemia with established atherosclerotic cardiovascular disease. It has been included in the latest National Reimbursement Drug List and is featured in the Chinese Expert Consensus on Comprehensive Management of Lipid-related Cardiovascular Risks (2025 Edition) and the County-level Guidelines for Rational Drug Use and Comprehensive Management of Dyslipidemia (2025 Edition).

Under this arrangement, Akeso, Inc. will receive a license fee of RMB80 million (tax inclusive) and milestone payments of up to RMB10 million (tax inclusive). Akeso Biopharma Co., Ltd. and AD Pharmaceuticals Co., Ltd., both indirect wholly owned subsidiaries of Akeso, Inc., will act as licensors, while JumpCan Pharmaceutical will take responsibility for commercialization and sales activities of 伊喜寧® in the authorized market. The product’s PCSK9 monoclonal antibody mechanism specifically binds to PCSK9 and blocks its interaction with LDL-R, restoring LDL-R expression levels and enhancing clearance of LDL-C from plasma, providing a new treatment option for long-term control of cardiovascular risks.